Recordati Rare Diseases Canada launched

13 April 2017

Recordati, a global biopharmaceutical company committed to providing orphan therapies to underserved rare disease communities, today announced the incorporation of its Canadian affiliate, Recordati Rare Diseases Canada Inc.

Recordati Rare Diseases Canada, a company wholly-owned by the Italy-based Recordati Group (REC: MI), will be the exclusive provider of several treatments, including Carbaglu (carglumic acid), Cystadane (betaine anhydrous) and Cosmegen (dactinomycin) in Canada.

"We're thrilled to be a part of Canada's innovative biopharmaceutical community focused on bringing treatments to ultra-rare disease and oncology patients," said Paul McCabe, general manager, Recordati Rare Diseases Canada, "adding: As a company, we're happy to be able to bring these products together under one umbrella to offer the highest-quality treatments to these patients."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK